Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 30, 2898-2904, December 1, 1970]
© 1970 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schlede, E.
Right arrow Articles by Conney, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schlede, E.
Right arrow Articles by Conney, A. H.

Stimulatory Effect of Benzo({alpha})pyrene and Phenobarbital Pretreatment on the Biliary Excretion of Benzo({alpha})pyrene Metabolites in the Rat1

Eva Schlede2, R. Kuntzman3 and A. H. Conney3

The Wellcome Research Laboratories, Burroughs Wellcome & Co. (U. S. A.) Inc., Tuckahoe, New York 10707

Benzo({alpha})pyrene (BP) metabolites are excreted into the bile at a slower rate after an i.v. injection of 14C-labeled BP than after an injection of 14C-labeled biliary metabolites of BP. Pretreatment of rats with BP or phenobarbital prior to the i.v. injection of 10 or 300 µg of BP-14C enhances the rate of excretion of metabolites of BP-14C into the bile. No effect of pretreatment was observed when 14C-labeled metabolites of BP, instead of BP-14C, were injected i.v., which indicates that pretreatment with BP or phenobarbital does not enhance the transport of BP metabolites into bile but enhances the formation of BP metabolites. The results described in this manuscript and elsewhere (14) indicate that pretreatment of rats with BP enhances the in vivo hydroxylation of BP-14C, whereas phenobarbital does not exert this effect. The data suggest that treatment of rats with phenobarbital prior to the administration of BP-14C may enhance the biliary excretion of BP-14C metabolites by enhancing the conjugation of hydroxylated BP metabolites.

1 Supported in part by Research Contract PH 43-65-1066 from the Pharmacology-Toxicology Programs, National Institute of General Medical Sciences, NIH.

2 Present address: Pharmakologisches Institut der Freien Universität, (Abt. Embryonal-Pharmakologie), 1 Berlin-Dahlem (33), Thielallee 69/73, West Germany.

3 Present address: Department of Biochemistry, Hoffmann-La Roche, Inc., Nutley, N. J. 07110.

Received 5/ 1/70. Accepted 8/19/70.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. H. Conney
Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture
Cancer Res., November 1, 2003; 63(21): 7005 - 7031.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1970 by the American Association for Cancer Research.